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Lokireddy S, Mouly V, Butler-Browne G, Gluckman PD,
Sharma M, Kambadur R, McFarlane C. Myostatin promotes the
wasting of human myoblast cultures through promoting ubiquitin-
proteasome pathway-mediated loss of sarcomeric proteins. Am J
Physiol Cell Physiol 301: C1316–C1324, 2011. First published Sep-
tember 7, 2011; doi:10.1152/ajpcell.00114.2011.—Myostatin is a
negative regulator of skeletal muscle growth and in fact acts as a
potent inducer of “cachectic-like” muscle wasting in mice. The
mechanism of action of myostatin in promoting muscle wasting has
been predominantly studied in murine models. Despite numerous
reports linking elevated levels of myostatin to human skeletal muscle
wasting conditions, little is currently known about the signaling
mechanism(s) through which myostatin promotes human skeletal
muscle wasting. Therefore, in this present study we describe in further
detail the mechanisms behind myostatin regulation of human skeletal
muscle wasting using an in vitro human primary myotube atrophy
model. Treatment of human myotube populations with myostatin
promoted dramatic myotubular atrophy. Mechanistically, myostatin-
induced myotube atrophy resulted in reduced p-AKT concomitant
with the accumulation of active dephosphorylated Forkhead Box-O
(FOXO1) and FOXO3. We further show that addition of myostatin
results in enhanced activation of atrogin-1 and muscle-specific RING
finger protein 1 (MURF1) and reduced expression of both myosin
light chain (MYL) and myosin heavy chain (MYH). In addition, we
found that myostatin-induced loss of MYL and MYH proteins is
dependent on the activity of the proteasome and mediated via
SMAD3-dependent regulation of FOXO1 and atrogin-1. Therefore,
these data suggest that the mechanism through which myostatin
promotes muscle wasting is very well conserved between species, and
that myostatin-induced human myotube atrophy is mediated through
inhibition of insulin-like growth factor (IGF)/phosphoinositide 3-ki-
nase (PI3-K)/AKT signaling and enhanced activation of the ubiquitin-
proteasome pathway and elevated protein degradation.
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MYOSTATIN is a secreted growth factor, belonging to a large
family of proteins collectively known as the transforming
growth factor- superfamily. Increased levels of myostatin are
inhibitory to skeletal muscle myogenesis and as such genetic
inactivation of myostatin in mice (21) or natural mutation of
the myostatin gene in sheep (6), cattle (15, 22), and humans
(28) results in a dramatic increase in skeletal muscle mass. In
addition to negatively regulating skeletal muscle myogenesis,
myostatin has been shown to act as a potent inducer of muscle
wasting. Systemic overexpression of myostatin in mice results
in reduced body mass, loss of adipose and muscle tissue, and
increased myofiber atrophy, all features consistent with ca-
chexia syndrome (40). Furthermore, addition of recombinant
myostatin protein to mouse C2C12 myotube cultures has been
shown to promote severe myotubular atrophy. This has been
revealed to be due to inhibition of insulin-like growth factor
(IGF)/phosphoinositide 3-kinase (PI3-K)/AKT signaling re-
sulting in enhanced FOXO1-mediated upregulation of compo-
nents of the ubiquitin-proteasome pathway, including atrogin-1
and muscle-specific E3 ubiquitin ligases muscle RING-finger 1
(MURF1) (20). In addition to studies involving animal models,
myostatin has been linked with numerous human conditions
that result in skeletal muscle wasting. Elevated myostatin
expression is associated with patients undergoing acute and
chronic human disuse atrophy (24), Type-II human muscle
fiber atrophy (36), and muscle unloading as a result of unilat-
eral lower limb suspension (12). Moreover elevated levels of
myostatin are observed in individuals suffering from chronic
illness such as end-stage liver disease (8), chronic obstructive
pulmonary disease (23), and advancing age-related muscle
wasting or sarcopenia (18, 37). Intramuscular and serum levels
of a myostatin-immunoreactive protein are also increased in
HIV-infected men undergoing skeletal muscle wasting when
compared with healthy controls (10).
In addition, a recent paper by Trendelenburg et al. (34)
demonstrated that treatment of human myotube cultures with
myostatin resulted in the development of myotube atrophy,
which is consistent with what is observed in rodent models
(20). Trendelenburg et al. (34) suggests that the myostatin-
mediated atrophy was due to inhibition of myogenic gene
expression and reduced protein synthesis, through blockade of
AKT/TORC1/p70S6K signaling. Trendelenburg et al. further
suggested that the myotube atrophy resulted primarily from
reduced protein synthesis, as opposed to increased protein
degradation via induction of atrogenes and the ubiquitin-pro-
teasome pathway (34), as previously shown (20).
Here we have studied in detail the mechanism(s) of action of
myostatin during human myotube atrophy to clarify the role of
myostatin in regulating myotube size and muscle protein deg-
radation in human skeletal muscle. Our results reveal that
myostatin-mediated human myotube atrophy is associated with
sarcomeric protein loss, inhibition of AKT signaling, and
enhanced expression of the ubiquitin E3 ligases atrogin-1 and
MURF1. Furthermore, we found that SMAD3 signaling is
critical for myostatin-dependent upregulation of FOXO1 and
atrogin-1 expression and subsequent sarcomeric protein deg-
radation through the ubiquitin-proteasome pathway.
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MATERIALS AND METHODS
Myostatin purification. Human recombinant myostatin protein
(hMstn) was cloned, expressed, and purified from Eschericia coli as
described (29). Myostatin-overexpressing Chinese hamster ovary
(CHO) cells (kindly provided by Dr. Se-Jin Lee) and purification of
murine myostatin (CHO-myostatin; CM) from these cells have been
described (21). Human primary myoblast cultures were treated with
CM at a final concentration of 10 ng/ml for all relevant experiments.
Cell culture. The human primary myoblast cell strain used in the
present study is designated as hMb15 (isolated from a 15-yr-old
healthy subject, provided by the BTR tissue bank affiliated with
EuroBioBank)(3, 7, 13). Human myoblast cultures were maintained at
37°C/5% CO2 in proliferation medium, which consists of Dulbecco’s
modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supple-
mented with 20% fetal bovine serum (FBS; Invitrogen), 10% horse
serum (HS; Invitrogen), and 1% chicken embryo extract (CEE; US
Biological, Swampscott, MA). To assess the ability of hMstn to
induce myotubular atrophy, human myoblasts were plated on Ther-
manox coverslips (Nunc, Roskilde, Denmark) at a density of 25,000
cells/cm2 and induced to differentiate under low serum conditions
(DMEM 2% HS). After 72 h differentiation, the cultures were treated
for an additional 24 h in differentiation media without or with 5 g/ml
hMstn. The cultures were then fixed with ethanol-formaldehyde-
glacial acetic acid (20:2:1) and stained with Gill’s hematoxylin and
1% eosin. Myotube area was assessed microscopically using the
Image-Pro Plus analysis software package (MediaCybernetics,
Bethesda, MD), with individual myotube area assessed for all myo-
tubes present in 10 random images taken from three coverslips per
treatment.
MG132 treatment. To study the role of proteasome-mediated pro-
tein degradation on hMstn-induced human myotube atrophy, hMb15
human myoblasts were differentiated (as described above) for 96 h
followed by an additional 24 h in the absence or presence of hMstn (5
g/ml). The proteasome inhibitor MG132 (Sigma-Aldrich, St. Louis,
MO) was added to the human myotube cultures at a concentration of
10 M during the final 10 h of hMstn treatment only. Cells were then
harvested for protein isolation and subsequent Western blot analysis.
Assessment of protein degradation in hMb15 myotubes. hMb15
myotubes were incubated with 5 Ci/ml [3H]tyrosine for 36 h to label
cellular proteins, according the previously mentioned protocol (11).
The medium was then switched to chase media containing 2 mM of
unlabeled tyrosine for 2 h to prevent the reincorporation of labeled
[3H]tyrosine. Myotubes were then incubated with fresh chase media in
the absence (dialysis buffer) or presence of hMstn for 24 h, with the
protease inhibitor MG132 added 12 h before media sample collection.
After collection, the medium was precipitated with 10% TCA and
centrifuged at 12,000 rpm for 10 min at 4°C. Acid-soluble radioac-
tivity was subsequently measured using a liquid scintillation counter
(1450 LSC and Luminescence counter; PerkinElmer Life Sciences,
Waltham, MA) and reflects the amount of prelabeled long-lived
protein degraded. The values are normalized to the total radioactivity
initially incorporated, and the graph represents the level of protein
degradation expressed as a percentage of initial.
Assessment of protein synthesis in hMb15 myotubes. Total protein
synthesis was assessed by measuring the rate of [3H]tyrosine incor-
poration in myotubes, as per the previously published protocol (35).
hMb15 myotubes (96 h differentiated) were treated in the absence
(dialysis buffer) or presence of hMstn for 24 h, followed by incubation
with medium containing 5 Ci/ml [3H]tyrosine for 2 h. After incu-
bation, the medium was discarded and the myotubes were washed
twice with PBS before addition of 1 ml 10% TCA to precipitate total
proteins. Total cell lysates were then collected and centrifuged at
1,200 rpm for 10 min at 4°C. The resulting pellet was washed with
95% ethanol and dissolved in 0.1 N NaOH at 25°C for 2 h with
rocking. These samples were analyzed for total radioactivity using a
liquid scintillation counter (1450 LSC and Luminescence counter;
PerkinElmer) with the level of radioactivity normalized to total
protein content. Results were expressed as counts per minute per
milligram of protein for each well, normalized the vehicle control.
Specific inhibitor of SMAD3 treatment. To study the role of
SMAD3 signaling during hMstn-mediated human myotube atrophy,
hMb15 human myoblasts were differentiated (as described above) for
96 h followed by a further 24 h in the absence (0.05% DMSO) or
presence of the SMAD3-specific inhibitor SIS3 (10 M; Sigma-
Aldrich) with or without hMstn (5 g/ml). Cells were then harvested
for protein isolation and subsequent Western Blot analysis.
siRNA-mediated knockdown of SMAD3. hMb15 human myoblasts
were seeded in six-well plates at a density of 25,000 cells/cm2. After
a 24-h attachment period, the cells were transfected with 30 nM of
each specific MISSION predesigned small interfering RNA (siRNA,
Sigma-Aldrich) using Lipofectamine 2000 reagent (Invitrogen) as per
the manufacturer’s guidelines. The myoblasts were then induced to
differentiate under low serum conditions (DMEM 2% HS) for 72 h
followed by a further 24 h in differentiation media with or without 3
g/ml hMstn. Cells were then harvested for protein isolation and
subsequent Western blot analysis. Details of each specific MISSION
predesigned siRNAs are provided below: MISSION siRNA Universal
Negative Control (SIC001; Scrambled siRNA); human SMAD3
siRNA-1, GAG UUC GCC UUC AAU AUG AdT dT; and human
SMAD3 siRNA-2, CAU GGA CGC AGG UUC UCC AdT dT.
Immunoprecipitation studies. For myosin heavy chain (MYH) and
myosin light chain (MYL) immunoprecipitation, hMb15 primary
myoblasts were differentiated for 96 h then incubated for an additional
24 h in the absence or presence of hMstn (5 g/ml). Cultures were
then harvested in 1 ml of RIPA buffer (50 mM NaF, 0.5% Na
deoxycholate, 0.1% SDS, 1% IGEPAL, 1.5 mM Na3VO4 and com-
plete protease inhibitor; Roche Molecular Biochemicals, Indianapolis,
IN) and centrifuged to remove cell debris. Bradford reagent (Bio-Rad,
Hercules, CA) was used to estimate total protein content to ensure
equal loading. Before immunoprecipitation, 250 g of total protein
was precleared using 25 l of a 50% Protein A-agarose slurry for 1 h
at 4°C. Immunoprecipitation of MYH and MYL was performed by
incubating the precleared lysate with 2 g of purified mouse mono-
clonal anti-MYH or purified mouse monoclonal anti-MYL, respec-
tively, for 2 h at 4°C. Protein A-agarose (Invitrogen) (50 l of 50%
percent), washed twice with RIPA buffer, was added for 1 h at 4°C,
followed by centrifugation to pellet immunoprecipitated complexes.
Pellets were washed four times with cold PBS, resuspended in 50 l
of 1 NuPAGE sample buffer (Invitrogen), and boiled for 5 min.
Immunoprecipitation samples were fractionated by SDS-PAGE and
transferred to nitrocellulose membrane by electroblotting for subse-
quent Western blot analysis.
Western blot and analysis. Preparation of protein extracts from
myoblasts and subsequent Western blot analysis have been previously
described in detail (33). Western blots were quantified by densitomet-
ric analysis using the GS-800 densitometer (Bio-Rad). Western blots
presented in this study are representative of at least two independent
experiments. Details of the antibodies used for Western analysis and
immunoprecipitation studies are provided below: mouse monoclonal
anti-MYL [T14; Developmental Studies Hybridoma Bank (DSHB),
Iowa City, IA]; mouse monoclonal anti-MYH (MF-20; DSHB); rabbit
polyclonal anti-pSMAD2/3 (sc-11769-R; Santa Cruz Biotechnology,
Santa Cruz, CA); goat polyclonal anti-SMAD2/3 (sc-6032; Santa
Cruz Biotechnology); rabbit polyclonal anti-atrogin-1 (gifted by Dr
Esther Latres); mouse monoclonal anti-MURF1 (gifted by Dr Esther
Latres); mouse monoclonal anti-ubiquitin (sc-8017; Santa Cruz Bio-
technology); rabbit polyclonal anti-FOXO1 (sc-11350; Santa Cruz
Biotechnology); rabbit polyclonal anti-p-FOXO1 (sc-101681; Santa
Cruz Biotechnology); rabbit monoclonal anti-FOXO3 (ab53287; Ab-
cam, Cambridge, MA); rabbit polyclonal anti-p-FOXO3 (sc-101689;
Santa Cruz Biotechnology); rabbit polyclonal anti-AKT (sc-8312;
Santa Cruz Biotechnology); rabbit polyclonal anti-p-AKT (sc-
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7985-R; Santa Cruz Biotechnology) and purified mouse monoclonal
anti-tubulin antibody (T-9026; Sigma-Aldrich).
Statistical analysis. Single comparisons were made using two-tail
Student’s t-tests and one-way ANOVA. Data are expressed as means 
SD, and P values 0.01 were considered significant. Experimental
replicates are described in relevant figure legends.
RESULTS
Treatment with myostatin results in dramatic myotube atro-
phy in human myoblast cell strains. Treatment of 72 h differ-
entiated hMb15 human myotube cultures with E. coli-produced
hMstn resulted in dramatic myotubular atrophy (Fig. 1A).
Specifically, we observed a 70% decrease in the number of
larger myotubes (15,000 m2) concomitant with a 83%
increase in the number of smaller (10,000 m2) myotubes in
the hMb15 cell strain following treatment with hMstn (Fig. 1,
B and C).
Treatment of human myotube cultures with hMstn induces
the loss of sarcomeric proteins and upregulation of compo-
nents of the ubiquitin-proteasome pathway. Western blot anal-
ysis of MYH and MYL sarcomeric protein expression in
hMb15 human myotube cultures treated with hMstn (Fig. 2A)
revealed decreased expression of both MYH and MYL in
hMstn-treated cells at all time points analyzed, consistent with
the myotubular atrophy observed following treatment with
hMstn. To independently confirm the functionality of the
hMstn recombinant protein, we also treated human myotube
cultures with eukaryotic-produced CHO cell-secreted recom-
binant myostatin protein (CM). Much akin to hMstn treatment,
addition of CM also led to reduced expression of both MYH
and MYL (Fig. 2B). Next, we analyzed the expression of
atrogin-1 and MURF1, two important ubiquitin E3 ligases,
which have proved to be robust markers for several forms of
skeletal muscle wasting (17). The results revealed a significant
increase in the expression of both atrogin-1 and MURF1 in the
hMb15 human myoblast cell strain following treatment with
hMstn (Fig. 2A). Furthermore, induction of myotubular atro-
phy through treatment with CM also resulted in an increase in
the abundance of atrogin-1 and MURF1 (Fig. 2B). These data
demonstrate that hMstn-induced human myotubular atrophy
results in a loss of sarcomeric proteins, which we suggest may
be due to increased protein degradation through the protea-
somal system.
Myostatin-mediated protein degradation is dependent on the
activity of the proteasome. Treatment of human myotubes
cultures with hMstn resulted in increased protein degradation,
as determined through quantifying the loss of [3H]tyrosine-
labeled cellular proteins after hMstn treatment (Fig. 2C). More-
over, addition of the proteasome inhibitor MG132, which has
been shown to block proteasome-mediated protein degradation
and thereby significantly increase protein content during atro-
phy (5, 31), prevented the elevated proteolysis observed fol-
lowing addition of hMstn (Fig. 2C). Thus hMstn treatment
results in enhanced protein degradation, which is mediated, at
least in part, through the action of the ubiquitin-proteasome
pathway.
To confirm whether or not hMstn-mediated degradation of
sarcomeric proteins occurs via the proteasomal system, MG132
was added to hMb15 myotube cultures in the presence or
absence of hMstn (Fig. 2D). As expected addition of hMstn
resulted in the loss of both MYH and MYL; however, blockade
of the proteasomal system, through addition of MG132, pre-
vented hMstn-mediated loss of both MYH and MYL (Fig. 2D).
Importantly, addition of MG132 had no appreciable effect on
either the basal expression of atrogin-1 and MURF1 or on the
ability of hMstn to enhance atrogin-1 and MURF1 expression
in the human myotube cultures (Fig. 2D).
To determine whether or not hMstn-mediated loss of MYH
and MYL resulted from enhanced ubiquitnation, MYH and
Fig. 1. Addition of human recombinant myosta-
tin protein (hMstn) results in the development of
severe human myotube atrophy. A: representa-
tive images of hMb15 human myoblasts differ-
entiated for 72 h, followed by an additional 24 h
with [72 h, 24 h (5 g/ml)] or without [72 h, 24
h ()] hMstn (5 g/ml). Myotube cultures were
fixed and stained with Gill’s hematoxylin and
eosin. Scale bar represents 50 m. B: frequency
distribution of myotube area (m2) over 3 cov-
erslips per treatment for the hMb15 human cell
strain. C: number of myotubes, sorted based on
myotube area, into small (10,000 m2), me-
dium (10,000 m2 to 15,000 m2), or large
(15,000 m2) groupings. Myotube area was
assessed for all myotubes present in 10 random
images per coverslip per treatment.
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MYL isoforms were specifically immunoprecipitated using
pan-MYH-and pan-MYL-specific antibodies and analyzed by
Western blot for the coimmunoprecipitation of ubiquitin using
a specific anti-ubiquitin antibody (Fig. 2E). Western blot anal-
ysis of ubiquitin that coimmunoprecipitated with MYH and
MYL from human myotube cultures treated with hMstn re-
vealed increased ubiquitination of both MYH and MYL fol-
lowing treatment with hMstn, with a characteristic ladder
profile, consistent with ubiquitination, visible only in hMstn-
treated human myotube cultures (Fig. 2E). These data suggest
that hMstn promotes human myotubular wasting and protein
degradation through increased ubiquitination of sarcomeric
proteins.
Addition of myostatin antagonizes the IGF-1 hypertrophy
signaling pathway and reduces protein synthesis during the
induction of human myotubular atrophy. The dephosphoryla-
tion and thus activation of FOXO transcription factors, such as
FOXO1, is critical to the ability of FOXO factors to induce
skeletal muscle wasting through regulation of so called atro-
phy-related genes or “atrogenes,” which include the well-
characterized ubiquitin E3 ligase atrogin-1 (26, 30). Therefore,
we next analyzed the expression of total FOXO1 and p-
FOXO1 in human myotube populations following treatment
with hMstn. Western blot analysis of FOXO1 and p-FOXO1
protein expression in hMb15 myotube cultures treated for a
period of 24 and 36 h with hMstn revealed increased expres-
sion of total FOXO1 and decreased abundance of p-FOXO1, at
24 and 36 h in the hMb15 cell strain following treatment with
hMstn (Fig. 3A). Similarly, when we treated hMb15 human
myotube cultures with CM, we also observed increased total
FOXO1 and reduced p-FOXO1 (Fig. 3B). Therefore, treatment
with either hMstn or CM resulted in the accumulation of
dephosphorylated and thus active FOXO1 in the human myo-
blast cultures.
Because the IGF/PI3-K/AKT pathway promotes the phos-
phorylation and subsequent inhibition of FOXO transcription
factors, we next analyzed whether or not myostatin signaling
antagonizes the action of the IGF/PI3-K/AKT pathway during
myostatin-mediated human skeletal muscle wasting. Consis-
tent with reversal of canonical IGF/PI3-K/AKT signaling, we
Fig. 2. Myostatin-induced human myotube atrophy results in
the loss of sarcomeric proteins in an ubiquitin-proteasome
pathway-dependent manner. Human myoblast cultures were
differentiated for 72 h followed by treatment with () or
without () hMstn (5 g/ml) for a further period of 24 or 36 h
differentiation. A: Western blot analysis of the expression of
MYH, MYL, MURF1, and atrogin-1 in hMb15 human myo-
tubes following treatment with hMstn. B: Western blot analysis
of MYH, MYL, MURF1, and atrogin-1 expression in hMb15
human myotubes following 24 h treatment without (CC) or with
eukaryotic-produced CHO cell-secreted recombinant myostatin
protein (CM). C: Western blot analysis of MYH, MYL,
MURF1, and atrogin-1 expression in hMb15 myotubes treated
with () or without () hMstn in the presence () or absence
() of the proteasome inhibitor MG132. D: sarcomeric proteins
were immunoprecipitated using pan-MYH- and pan-MYL-spe-
cific antibodies and subjected to Western blot using a specific
anti-ubiquitin antibody. The visible mobility shift (ladder pro-
file) of MYH and MYL proteins as a result of hMstn treatment
is consistent with ubiquitination. The expression of tubulin was
assessed to ensure equal loading of samples. E: hMstn increases
protein degradation in differentiated myotubes. Differentiated
myotubes were incubated with [3H]tyrosine for 36 h and then
treated with either hMstn or MG132 or a combination of both.
Medium was collected at 24 h, and the amount of degraded
[3H]tyrosine-labeled protein was expressed as a percentage of
the initial amount of [3H]tyrosine added. ***P  0.001. Error
bars represent means  SD (n 	 4).
C1319MYOSTATIN AND HUMAN MUSCLE WASTING
AJP-Cell Physiol • VOL 301 • DECEMBER 2011 • www.ajpcell.org
found that treatment with either hMstn or CM reduced the
abundance of p-AKT in the hMb15 human myotube cultures
(Fig. 3, C and D). Previously published data have demonstrated
that treatment with excess myostatin inhibits protein synthesis
(32). Moreover, reduced AKT/mammalian target of rapamycin
(mTOR) protein synthesis signaling and increased atrophy was
observed following overexpression of myostatin in muscle (1)
and in response to treatment of myotubes with recombinant
myostatin protein (34). As we observed reduced p-AKT (Fig.
3, C and D) we next assessed whether or not hMstn treatment
resulted in reduced protein synthesis in the human myotube
cultures. As shown in Fig. 3E, treatment of human myotubes
cultures with hMstn resulted in reduced protein synthesis, as
measured through [3H]tyrosine incorporation, at both 12 and
24 h treatment (Fig. 3E).
Therefore, these data suggest that myostatin promotes hu-
man skeletal muscle wasting through both inhibiting protein
synthesis as well as antagonising IGF/PI3-K/AKT signaling,
thereby blocking AKT-mediated phosphorylation of FOXO1,
leading to increased expression of both activated FOXO1 and
FOXO1 downstream target genes, including atrogin-1.
Myostatin signals through SMAD3 to regulate atrogin-1 and
FOXO1 during myostatin-induced human myotube atrophy. To
determine whether or not SMAD3 signaling is important in
hMstn-mediated human myotube atrophy, hMb15 human myo-
tube cultures were treated with hMstn in the presence or
absence of SIS3, which has previously been shown to specif-
ically inhibit SMAD3 function through suppressing SMAD3
phosphorylation (14). As expected, treatment with SIS3 re-
sulted in both a reduction in endogenous p-SMAD3 expres-
Fig. 3. Myostatin-induced human myotube
atrophy results in enhanced activation of
Forkhead Box-O (FOXO1) and inhibition of
insulin-like growth factor (IGF)/phosphoino-
sitide 3-kinase (PI3-K)/AKT signaling. Hu-
man myoblast cultures were differentiated for
72 h followed by treatment with () or with-
out () hMstn (5 g/ml), or without (CC) or
with CM for a further period of 12, 24, or 36
h differentiation. A and B: Western blot anal-
ysis of FOXO1 and p-FOXO1 expression in
hMb15 human myotube cultures following
treatment with either hMstn (A) or CM (B). C
and D: Western blot analysis of AKT and
p-AKT expression in hMb15 human myotube
cultures following treatment with either
hMstn (C) or CM (D). The expression of
tubulin was assessed to ensure equal loading
of samples. Graphs represent densitometric
analysis of Western blots [FOXO1, p-FOXO1
(A and B), AKT and p-AKT (C and D)],
normalized to tubulin expression. The abun-
dance of p-FOXO1 is expressed as a propor-
tion of total FOXO1 (A and B) and the abun-
dance of p-AKT is expressed as a proportion
of total AKT (C and D). E: hMstn decreases
protein synthesis in differentiated myotubes.
Differentiated myotubes were treated with
hMstn for 24 h, followed by a further incuba-
tion with [3H]tyrosine for 2 h. Total cell ly-
sates were collected and the level of protein
synthesis, as measured via [3H]tyrosine incor-
poration, was assessed and expressed as counts
per minute (cpm) normalized to total protein
content (cpm/mg protein). ***P  0.001. Error
bars represent means  SD (n 	 6).
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sion, when compared with untreated control, and also blocked
the ability of hMstn to promote phosphorylation of SMAD3 in
the hMb15 myotube cultures (Fig. 4A). While addition of
hMstn to control treated (0.05% DMSO) hMb15 myotube
cultures resulted in an increase in the expression of atrogin-1,
FOXO1, MURF1, and FOXO3, concomitant with reduced
expression of MYH (Fig. 4, B and C), addition of SIS3 to
hMstn-treated hMb15 myotube cultures blocked the ability of
hMstn to enhance the expression of atrogin-1 and FOXO1 and
also prevented loss of MYH (Fig. 4B). Similarly, knockdown
of SMAD3 through transfection of SMAD3-specific siRNA
also interfered with hMstn-mediated upregulation of FOXO1
and atrogin-1 and subsequent loss of MYH (Fig. 4D). Inter-
estingly, hMstn treatment was still able to enhance the protein
expression of MURF1 and FOXO3 despite the inhibition of
SMAD3 through SIS3 treatment (Fig. 4C), suggesting that
Fig. 4. The SMAD3 signaling pathway plays a
critical role during myostatin-induced human myo-
tube atrophy. Human myoblast cultures were dif-
ferentiated for 72 h followed by treatment with ()
or without () hMstn (5 g/ml) in the presence
() or absence () of the SMAD3-specific inhib-
itor SIS3 for a further period of 24 h differentia-
tion. Western blot analysis of the expression of
SMAD3 and p-SMAD3 (A); atrogin-1, FOXO1,
and MYH (B); and MURF1, FOXO3, and
p-FOXO3 (C) following treatment with () or
without () hMstn in the presence () or absence
() of SIS3. The abundance of p-SMAD3 is ex-
pressed as a proportion of total SMAD3 (A) and
the abundance of p-FOXO3 is expressed as a
proportion of total FOXO3 (C). D: Western blot
analysis of the expression of SMAD2/3, atrogin-1,
FOXO1, and MYH following treatment with ()
or without () hMstn in hMb15 myoblasts trans-
fected with Universal Negative Control [Scram-
bled small interfering RNA (siRNA)] and
SMAD3-specific siRNAs (SMAD3 siRNA-1 and
SMAD3 siRNA-2). The expression of tubulin was
assessed to ensure equal loading of samples.
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hMstn requires active SMAD3 signaling to regulate both
FOXO1 and atrogin-1 and for regulation of sarcomeric protein
expression, whereas SMAD3 is dispensable for hMstn regula-
tion of FOXO3 and MURF1.
DISCUSSION
In this present study, we have assessed the effect of the
pro-cachectic growth factor myostatin on human skeletal mus-
cle myotube cultures, in an effort to gain better understanding
of the mechanism through which myostatin promotes skeletal
muscle wasting (Fig. 5). Using a human primary myoblast
culture model, E. coli-produced hMstn, and eukaryotic-pro-
duced CHO cell-secreted recombinant myostatin protein (CM),
we show that human myostatin promotes human myotube
wasting by activating the ubiquitin-proteasome pathway. Con-
sistent with studies using murine myoblast models (20), hMstn
and CM treatment induced the expression of atrogin-1 and
MURF1 (Fig. 2, A and B), two muscle-specific ubiquitin E3
ligases shown to be upregulated in numerous form of muscle
wasting (17). Myostatin-induced human myotube atrophy fur-
ther resulted in the loss of critical sarcomeric proteins in the
human myotube cultures, which was due to the action of the
ubiquitin-proteasome pathway as hMstn treatment resulted in
enhanced ubiquitination of both MYH and MYL isoforms (Fig.
2E). Moreover, MG132-mediated blockade of hMstn-induced
protein degradation resulted in a rescue of both MYH and
MYL expression (Fig. 2, C and D). Targeted degradation of
sarcomeric proteins, such as MYH and MYL, through the
ubiquitin-proteasome pathway is not a new concept. In fact,
treatment of C2C12 myotube cultures with the artificial gluco-
corticoid dexamethasone (Dex) has been recently demonstrated
to promote wasting through MURF1-dependent degradation of
MYH and MYL isoforms (5). Although we find that hMstn
treatment results in the loss of MYH and MYL, unlike Dex-
induced myotube atrophy, myostatin appears to preferentially
signal through atrogin-1, not MURF1, to promote the loss of
sarcomeric proteins in human myotube cultures. In fact we
demonstrated that, in human cultures with impaired SMAD3
signaling, the expression of MURF1 remained elevated follow-
ing hMstn treatment; however, loss of SMAD3 signaling
prevented hMstn-mediated upregulation of atrogin-1 and
FOXO1 and importantly also prevented hMstn-mediated loss
of MYH (Fig. 4). Taken together, these data further suggest
that the function of atrogin-1 and MURF1 may vary in re-
sponse to different cachectins. In support, although both
atrogin-1 and MURF1 are upregulated in response to Dex
treatment (5, 26), absence of MuRF1, not Atrogin-1, protects
against Dex-induced muscle loss (2).
Previously published results indicate that myostatin is able
to activate FOXO1 during murine myotubular atrophy (20).
However, the current results reveal that, in addition to FOXO1,
hMstn was also able to induce FOXO3 during human myotube
atrophy. Interestingly, unlike FOXO1, hMstn was still able to
enhance FOXO3 expression in the absence of SMAD3 (Fig.
4C). Since myostatin-induced human myotube atrophy has
been shown to result in enhanced phosphorylation of SMAD2
(34), we suggest that hMstn regulation of FOXO3 in the human
myotube cultures may be mediated through a SMAD2-depen-
dent mechanism. It is noteworthy to mention that FOXO3 has
been recently shown to promote autophagy in skeletal muscle
through regulating the expression of autophagy-related genes
such as LC3 and Bnip3 (19, 38). Therefore, enhanced activa-
tion of FOXO3 in response to myostatin treatment may pro-
mote autophagy in the human myotube atrophy model; how-
Fig. 5. Myostatin promotes dramatic wasting in human myotube cultures via
the ubiquitin-proteasome pathway. Myostatin-mediated human myotube atro-
phy results in enhanced FOXO1 expression via a mechanism involving
canonical SMAD3 signaling. Through inhibition of AKT phosphorylation,
myostatin treatment results in the accumulation of active dephosphorylated
FOXO transcription factors, which further results in the activation of FOXO
target genes, including atrogin-1 and MURF1, leading to the ubiquitination of
critical sarcomeric proteins and most likely protein synthesis machinery
(eIF3-f), increased protein degradation, reduced protein synthesis, and the
development of myotubular atrophy in the human myotube cultures. Arrows
represent stimulation and blunt-ended lines represent inhibition.
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ever, further work will need to be performed to verify a role for
myostatin regulation of FOXO3 and the induction of au-
tophagy during skeletal muscle wasting.
In addition to the increased expression of FOXO3, we also
found a SMAD3-independent increase in MURF1 expression
following treatment with hMstn (Fig. 4C), thus we propose that
FOXO3 may be important for myostatin regulation of MURF1
expression. In fact, previous studies have shown that activation
of FOXO3 is linked with increased abundance of MURF1,
enhanced protein degradation, and development of skeletal
muscle wasting (4, 25, 39). Although we found enhanced
accumulation of active dephosphorylated FOXO3 and elevated
MURF1 expression following treatment with hMstn, the data
presented here suggest that myostatin-mediated degradation of
sarcomeric proteins during human myotube atrophy occurs
predominantly via a FOXO1/atrogin-1 mechanism rather than
through FOXO3/MURF1. Therefore, further work will need to
be performed to clarify the role of MuRF1 in myostatin-
mediated human muscle wasting.
Previously published results by Taylor et al. (32) indicate
that treatment of C2C12 myotubes with excess myostatin
results in decreased protein synthesis, with no appreciable
change in the rate of protein degradation. Furthermore, a recent
paper by Trendelenburg et al. (34) provides evidence to sug-
gest that myostatin-mediated human myotube atrophy results
from inhibition of the AKT/TORC1/p70S6K protein synthesis-
signaling pathway rather than from increased protein degrada-
tion. In agreement with previously published reports, we also
found reduced protein synthesis as well as reduced phosphor-
ylation of AKT and the AKT downstream target FOXO1
following treatment of human myotubes cultures with either
hMstn or CM (Fig. 3). However, in contrast to the work of
Trendelenburg et al. we found elevated expression of the
ubiquitin E3 ligases atrogin-1 and MURF1. Moreover, we also
observed enhanced ubiquitination and subsequent proteasome-
dependent protein degradation and loss of sarcomeric proteins
during hMstn-induced human myotube wasting (Fig. 2). We
suggest that the disparity between what we observed in the
present study and the published data of Taylor et al. and
Trendelenburg et al. may be due to the different model system
used as well as the differences in recombinant myostatin
protein used. Nevertheless, these data presented in this current
study are in agreement with recently published work, which
demonstrates the capacity for myostatin signaling to promote
atrogin-1 promoter activity (27), as well as previously pub-
lished work from our lab demonstrating enhanced protein
ubiquitination and elevated expression of atrogin-1 and
MURF1 following addition of excess myostatin to mouse
model systems (20). Absence of myostatin has also been
shown to prevent upregulation of atrogin-1 and MURF1 as
well as the increased 20S proteasome activity observed during
Dex-induced muscle wasting (9). Elevated ubiquitination,
atrogin-1, and MURF1 expression, detected in C26 tumor-
bearing mice undergoing muscle wasting, has also been shown
to correlate with elevated myostatin expression and impor-
tantly was reversed upon treatment with sActRIIB myostatin
antagonist (39).
It is important to mention that in addition to promoting the
degradation of MYH and MYL, as shown here, atrogin-1 can
also target eukaryotic initiation factor 3 subunit f (eIF3-f) for
ubiquitination and subsequent degradation (16). Activation of
eIF3-f prevents myotube atrophy and in fact results in hyper-
trophy and enhanced muscle structural protein expression.
Conversely, loss of eIF3-f has been shown to result in myotube
atrophy (16). Thus myostatin may also promote sarcomeric
protein loss through atrogin-1-mediated degradation of trans-
lation machinery, such as eIF3-f, which is consistent with the
reduced protein synthesis observed following treatment with
hMstn (Fig. 3E). However, as we observed enhanced ubiquiti-
nation of both MYH and MYL following treatment with hMstn
(Fig. 2E), we believe that direct ubiquitination and thus deg-
radation of sarcomeric proteins also occurs in response to
hMstn treatment. Therefore, taken together, we propose that a
combination of targeted degradation of sarcomeric proteins
together with degradation of protein synthesis machinery may
result in the sarcomeric protein loss and skeletal muscle wast-
ing observed following treatment with hMstn.
In this paper we have described a mechanism which suggests
that myostatin-induced human myotube atrophy results from
reduced protein synthesis, impaired IGF/PI3-K/AKT signaling,
and enhanced sarcomeric protein degradation, preferentially
through SMAD3-dependent, FOXO1-mediated, activation of
atrogin-1 and the ubiquitin-proteasome pathway (Fig. 5).
Given that inhibition of myostatin leads to increased postnatal
skeletal muscle growth, and excess levels of myostatin pro-
motes dramatic skeletal muscle wasting, we propose that myo-
statin antagonists would have tremendous therapeutic value in
alleviating human skeletal muscle wasting.
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